Intelligent Pan-Antiallergy Vaccine Development System

Publication ID: 24-11857623_0003_PTD

Published: October 28, 2025

Category:Synergistic Combinations

Legal Citation

pr1or.art Inc., “Intelligent Pan-Antiallergy Vaccine Development System,” Published Technical Disclosure No. 24-11857623_0003_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857623_0003_PTD

This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,623.

Summary of the Inventive Concept

A novel system integrating AI, IoT, blockchain, and nano-particle technologies to develop personalized, targeted, and effective pan-antiallergy vaccines

Background and Problem Solved

The original pan-antiallergy vaccine patent, while a significant breakthrough, has limitations in terms of scalability, personalization, and real-time monitoring. The new inventive concept addresses these limitations by combining the patented protein construct with advanced technologies to create a more powerful and adaptive system.

Detailed Description of the Inventive Concept

The system consists of a blockchain-based database for storing and managing genetic data of IgE motif segments, a machine learning module for predicting optimal scaffold segments, and an IoT-enabled sensor for detecting and monitoring IgE levels in subjects. The system integrates with an AI-powered recommendation engine to select optimal protein constructs for personalized vaccines. Additionally, a nano-particle carrier system is used for targeted delivery of the protein construct to immune cells. The system also includes a cloud-based analytics platform for real-time monitoring of vaccine efficacy.

Novelty and Inventive Step

The new claims introduce the integration of AI, IoT, blockchain, and nano-particle technologies with the patented protein construct, enabling personalized, targeted, and adaptive pan-antiallergy vaccines. This synergistic combination is novel and non-obvious compared to the original patent.

Alternative Embodiments and Variations

Alternative embodiments include using different AI models, IoT devices, or blockchain protocols. Variations could include integrating additional technologies, such as CRISPR gene editing, or applying the system to other types of vaccines or immunotherapies.

Potential Commercial Applications and Market

The Intelligent Pan-Antiallergy Vaccine Development System has significant commercial potential in the vaccine and immunotherapy markets, with potential applications in personalized medicine, precision health, and disease prevention.

CPC Classifications

Section	Class	Group
A	A61	A61K39/395
A	A61	A61K2039/544
A	A61	A61K2039/555

Section 103 Obviousness Analysis (PHOSITA)

▼

Field of Art

Immunology, Biotechnology, and Vaccine Development with specialization in protein engineering, immunomodulation, and computational biology techniques

Person of Ordinary Skill (PHOSITA) Profile

A researcher with advanced degrees in biotechnology or immunology, proficient in protein modeling, AI-assisted design techniques, computational biology tools, and understanding of IgE-mediated immune responses

Obviousness Rationale

A PHOSITA would recognize that integrating computational technologies with protein construct design represents a natural progression in vaccine development. The blockchain, AI, and IoT technologies proposed are well-established computational approaches for enhancing biological research methodologies. The nano-particle delivery system and personalized vaccine approach are logical extensions of existing protein engineering principles demonstrated in the source patent.

Obvious Combinations & Variations

Source Patent Element

Computer modeling of scaffold proteins from extracellular adherence protein domain

PTD Variation

AI-powered machine learning module for predicting optimal scaffold segments

Obviousness Reasoning

Computational protein design is a predictable evolution of existing modeling techniques, representing an obvious application of advanced machine learning to existing protein engineering approaches

Source Patent Element

Protein construct with IgE motif segment insertion

PTD Variation

Blockchain-based database for storing and managing genetic data of IgE motif segments

Obviousness Reasoning

Data management technologies are a known technique for organizing complex genetic information, providing a predictable enhancement to existing protein construct research methodologies

Source Patent Element

Pharmaceutical composition for immunological intervention

PTD Variation

Nano-particle carrier system for targeted delivery of protein constructs to immune cells

Obviousness Reasoning

Advanced drug delivery technologies represent a foreseeable improvement in vaccine development, utilizing well-understood principles of targeted molecular transport

Source Patent Element

Method for generating protein constructs involving computer modeling

PTD Variation

Generative AI model for generating novel scaffold segments with blockchain validation

Obviousness Reasoning

Applying emerging AI technologies to protein design is a logical extension of existing computational biology techniques, representing an obvious combination of known methodological approaches

Source Patent Element

Protein construct for immunological intervention

PTD Variation

IoT-enabled sensor for detecting and monitoring IgE levels with cloud-based analytics

Obviousness Reasoning

Real-time monitoring and data analysis are predictable technological enhancements in medical research, representing an obvious application of existing sensor and cloud computing technologies

35 U.S.C. § 103 Summary: Based on the teachings of US Patent 11857623 and the disclosed technological variations, a person having ordinary skill in the art would find the proposed pan-antiallergy vaccine development system and associated methods to be obvious extensions of existing protein engineering and computational biology techniques. The integration of AI, blockchain, IoT, and nano-particle technologies represents a predictable combination of known methodological approaches in immunological research and vaccine development.

Original Patent Information

Patent Number	US 11,857,623
Title	Pan-antiallergy vaccine
Assignee(s)	King Abdulaziz University